Table 1. Baseline Characteristics of Study Participants

Varenicline (n=355)Placebo (n=359)
*n=352 (varenicline); n=348 (placebo).
†n=354 (varenicline); n=358 (placebo). Scores range from 0 to 10, with higher scores indicating greater nicotine dependence.
Demographic characteristics
    Age, mean (SD), y57.0 (8.6)55.9 (8.3)
    Gender (male), n (%)267 (75.2)295 (82.2)
    Race, n (%)
        White285 (80.3)290 (80.8)
        Black3 (0.8)2 (0.6)
        Asian30 (8.5)31 (8.6)
        Other37 (10.4)36 (10.0)
    Body mass index, mean (SD), kg/m2*27.5 (4.4)27.9 (4.5)
Smoking history
    Time smoking cigarettes, mean (range), y40 (5–63)39 (12–60)
    Cigarettes/d (past month), mean (range)22.1 (10–60)22.9 (10–80)
    Noncigarette tobacco use in past month, n (%)13 (3.7)26 (7.2)
    Fagerström test for nicotine dependence score, mean (SD)5.6 (2.1)5.7 (2.0)
    Any previous serious attempts to quit, n (%)304 (85.6)310 (86.4)
Medical history, n (%)
    Cardiac disease
        Angina pectoris189 (53.2)172 (47.9)
        MI163 (45.9)188 (52.4)
        Prior coronary revascularization164 (46.2)185 (51.5)
        Congestive heart failure16 (4.5)14 (3.9)
        Atrial fibrillation10 (2.8)15 (4.2)
    Cerebrovascular disease
        Stroke16 (4.5)24 (6.7)
        Transient ischemic attack20 (5.6)21 (5.8)
    Vascular disease
        Hypertension195 (54.9)202 (56.3)
        Peripheral arterial disease82 (23.1)97 (27.0)
        Prior peripheral revascularization37 (10.4)42 (11.7)
        Aortic aneurysm0 (0.0)2 (0.6)
    Diabetes mellitus47 (13.2)60 (16.7)